On July 10, Moderna declined 5.51% in regular trading, trading at $71.39/share, with turnover of $86.72 million, extending its multi-session pullback from recent highs.

On the news front, Bank of America maintained its underperform rating on the stock, with a target price of $38 — representing a discount of more than 50% to the current share price and significantly below the FactSet consensus target of $50.53. The bank also flagged that Moderna's upcoming second-quarter earnings release on July 31 could face heightened market scrutiny.

Moderna had previously surged over 18% following its seasonal flu vaccine candidate mRNA-1010 receiving unanimous 9-0 support from the FDA's Vaccines and Related Biological Products Advisory Committee, with a final regulatory decision expected on August 5. Market participants have largely priced in these catalysts. The combination of an institutional bearish stance and sustained profit-taking pressure following the sharp rally continues to weigh on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)